Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josef Thaler

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Haematologica|March 8, 2005
The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alphaJoerg Hasford, Markus Pfirrmann, Pat Shepherd, et al.
Wiener Klinische Wochenschrift|March 29, 2013
Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosisSonja Burgstaller, Michael Fridrik, Sabine Hojas, et al.
Cancer|February 10, 2010
Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedicationSalvatore Siena, Robert Glynne-Jones, Antoine Adenis, et al.
Leukemia Research|August 4, 2004
Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemiaWolfgang Eisterer, Oliver Bechter, Ola Söderberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL StudyHansjochen Wilke, Robert Glynne-Jones, Josef Thaler, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 2, 2009
Are gender-associated differences in quality of life in colorectal cancer patients disease-specific?Johannes Giesinger, Georg Kemmler, Verena Mueller, et al.
Anticancer Research|December 27, 2011
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT)Ewald Wöll, Richard Greil, Wolfgang Eisterer, et al.
Anticancer Research|October 7, 2017
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3Ewald Wöll, Josef Thaler, Felix Keil, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 24, 2017
A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patientsGudrun Piringer, Michael Fridrik, Alfred Fridrik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2010
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II studyHeinz Ludwig, Zdenek Adam, Roman Hajek, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Haematologica|March 8, 2005
The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alphaJoerg Hasford, Markus Pfirrmann, Pat Shepherd, et al.
Wiener Klinische Wochenschrift|March 29, 2013
Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosisSonja Burgstaller, Michael Fridrik, Sabine Hojas, et al.
Cancer|February 10, 2010
Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedicationSalvatore Siena, Robert Glynne-Jones, Antoine Adenis, et al.
Leukemia Research|August 4, 2004
Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemiaWolfgang Eisterer, Oliver Bechter, Ola Söderberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2008
Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL StudyHansjochen Wilke, Robert Glynne-Jones, Josef Thaler, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 2, 2009
Are gender-associated differences in quality of life in colorectal cancer patients disease-specific?Johannes Giesinger, Georg Kemmler, Verena Mueller, et al.
Anticancer Research|December 27, 2011
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT)Ewald Wöll, Richard Greil, Wolfgang Eisterer, et al.
Anticancer Research|October 7, 2017
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3Ewald Wöll, Josef Thaler, Felix Keil, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 24, 2017
A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patientsGudrun Piringer, Michael Fridrik, Alfred Fridrik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2010
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II studyHeinz Ludwig, Zdenek Adam, Roman Hajek, et al.
Pageof 8